
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: a regulatory first for biosimilars, a bispecific built for durability in the eye, and a move to make CAR-T therapy same-day.
First,
Next,
And finally,
That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.
Key takeaways
- Biosimilar efficiency: Pebrilzo’s approval is an early test of whether developers can skip comparative efficacy trials for monoclonal antibody biosimilars.
- Durability race: ASCEND will test whether VIS-101 can stretch the time between wet AMD injections beyond what current therapies allow.
- In vivo cell therapy: Verismo is joining the push to make CAR-T off-the-shelf and same-day, though clinical proof is still ahead.
Related to this article









